Active ad and exact outbound link observed in Meta Ad Library on October 22, 2026. The page image and section source are the existing October 20 capture of this destination. Offers and product selections may change. Selection reflects creative and page structure; performance is not available.

Want GLP-1 benefits without the needle? · capsule visual. Product benefits lead into subscription plans, gifts, a goal calculator, testimonials, and ingredient research. Compare the creative with the destination and explore the other ads sharing this route.
Selected for its design and offer structure. Ad performance isn’t available in this collection.
The question names the exact objection a lot of people have to GLP-1 medications, and the image answers it visually: where you'd expect a needle, there's a capsule held up between two fingers. That swap is the whole ad, and it reads in a second. The jar on an open palm at the bottom makes the product feel like something offered to you, which suits the gentle, objection-handling tone. The Absorption Company ran several versions of this static on Meta from October 8, 2026, using the same primary text as its burn-more-at-rest static.
The question gets a visual answer but not a factual one. The viewer is left asking whether a capsule can really do what a shot does, and the creative offers no supported proof point, customer line or study note to answer it. The copy's claim of no side effects is broad, and it isn't backed up anywhere in the ad. If you make an objection-handling ad like this, answer the question with the one fact you can support best, right under the visual, and give the viewer a low-risk way to try it, like a guarantee.
It replaces the expected needle with a capsule, so the objection and the answer appear together.
It shows what you'd actually receive and presents it as an easy offer.
It lists the reasons someone might want an alternative to injections.
It restates the core difference for viewers who only read the bottom line.
No price or discount appears. The value framing is avoiding a prescription and the cost of shots.
The ad sends people to the WLP-1 product page, a standard product page rather than a focused landing page, and it's one of 30 ads in the Fluid library pointing there. It opens on WLP-1 with plan choices, then explains the product and shows testimonials, an expert section and clinical trials. For an ad built around an objection, the page's most relevant answers (the clinical trials and what others are saying) sit well below the plans. A short comparison near the top, showing what you get with the capsule versus a shot, would answer the ad's question at the moment the viewer arrives.
The Absorption Company's WLP-1 product page, pitched as oral GLP-1 support, with a claims strip, a 70-Day Challenge gift offer, subscription plans, video testimonials, clinical study cards and a stack upsell. 30 Absorption Company ads in the Fluid library link here, led by Halloween cravings statics and "no needles" comparison statics.
Shows the jar beside the product name, rating and claimed outcomes, answering what WLP-1 is and what it's said to do.
Offers 3 Months, 6 Months and Monthly with savings, free gifts and the 70-Day Challenge, answering what it costs and why to subscribe.
Explains the brand's mechanism claims, answering how the product is supposed to work.
Describes what the brand says changes over time, answering when to expect anything.
Shows vertical videos with each reviewer's name and time on the product, answering what real users say.
An expert quote card with a headshot and a clinicians' choice badge, answering whether professionals back it.
Quotes study findings as sourced cards, answering what evidence the claims rest on.
Asks why stop at three metabolic pathways, answering what to add and raising order size.
Suggests complementary products and collects customer reviews, answering what else to buy and what buyers say.
Read the full breakdown of this page
One of 188 The Absorption Company ads in the Fluid Inspiration Library, captured from the Meta Ad Library on Oct 22, 2026. We record that an ad ran publicly, not how it performed.